Please login to the form below

Not currently logged in

David Meek leaves Novartis to join Endocyte as first chief commercial officer

Joins shortly after major oncology deal with Merck & Co

US biopharma company Endocyte has appointed Novartis' David Meek to the newly created role of chief commercial officer.

Meek leaves Novartis after more than seven years at the Swiss pharma firm where he was most recently the head of northern and central Europe oncology.

Previously, he served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products, and he also served as the global business franchise head for Novartis' respiratory and dermatology franchise in Basel, Switzerland.

In his new role, Meek will be responsible for the development of Endocyte's commercial team and the company's overall commercial strategy and execution, which includes the deal with Merck & Co made in April, 2012, involving Endocyte's cancer drug vintafolide.

In addition to this drug, Endocyte's products in development include etarfolatide and other targeted small molecule drug conjugates.

"I'm very excited to join the Endocyte team, where I have been compelled by the company's approach to develop innovative therapies accompanied by companion diagnostics," said Meek.

Prior to his time at Novartis, Meek spent 15 years at Johnson & Johnson (J&J), where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

30th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company

WE’s global and European healthcare hub is based in London, and works with experienced teams across the globe; teams encompassing...

Latest intelligence

Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...
Thoughts on the intersection between technology and psychology
Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology...
Learning to listen - Examining the opportunities and challenges of using conversations on social media for Pharma brands
The world in which we do business has markedly changed since 2008, which has helped to increase the push towards the ‘digitisation’ of marketing communications’ channels, This feature explores the...